1 月 8, 2024 in Press Release

HighField Biopharmaceuticals HF1K16 1a 期数据表明新型免疫肿瘤药物对实体瘤安全、耐受性良好且有效

HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors HANGZHOU, China--January 8, 2024--HighField Biopharm ...

阅读更多
12 月 18, 2023 in Press Release

HighField Biopharmaceuticals 在 HFK1(一种独特的免疫脂质体,用于治疗 HER2 低和 HER2+ 癌症)的 1 期试验中向第一位患者给药

HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers The company’s groundbreaking drug encapsulated immun ...

阅读更多
10 月 23, 2023 in Press Release

HighField Biopharmaceuticals 宣布 HF1K16 的 1a 期阳性数据,这是一种新的免疫肿瘤药物,用于治疗复发性和难治性胶质瘤患者

HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma HighField CEO Yuhong Xu and CBO Donald Wyatt ...

阅读更多
发布占位符图片
7 月 17, 2023 in Press Release

HighField Biopharmaceuticals 宣布 HF1K16 治疗复发性和难治性胶质瘤的 1b/2 期试验中第一位患者接受给药

HF1K16 is a new immuno-oncology drug targeting myeloid-derived suppressor cells (MDSC) to treat cancerHANGZHOU, CHINA--HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology co ...

阅读更多
发布占位符图片
6 月 13, 2023 in Press Release

HighField Biopharmaceuticals 获得美国 FDA IND 批准免疫脂质体 HF158K1 用于治疗 HER2 低和 HER2+ 癌症的 1 期试验

The company’s groundbreaking drug encapsulated immunoliposomes may represent a significant improvement over existing antibody drug conjugatesHANGZHOU, China--June 13, 2023--HighField Biopharmaceutical ...

阅读更多